38 related articles for article (PubMed ID: 7771500)
1. What Lies behind Paraneoplastic Hypercalcemia Secondary to Well-Differentiated Neuroendocrine Neoplasms? A Systematic Review of the Literature.
Giannetta E; Sesti F; Modica R; Grossrubatscher EM; Ragni A; Zanata I; Colao A; Faggiano A
J Pers Med; 2022 Sep; 12(10):. PubMed ID: 36294693
[TBL] [Abstract][Full Text] [Related]
2. Parathyroid hormone-related peptide in pancreatic neuroendocrine tumours associated with hypercalcaemia.
Papazachariou IM; Virlos IT; Williamson RC
HPB (Oxford); 2001; 3(3):221-5. PubMed ID: 18333019
[TBL] [Abstract][Full Text] [Related]
3. Severe hypercalcaemia and lymphoma in an HTLV-1 positive Jamaican woman: a case report.
Lyell V; Khatamzas E; Allain T
J Med Case Rep; 2007 Jul; 1():56. PubMed ID: 17651486
[TBL] [Abstract][Full Text] [Related]
4. PTHrP, calcitonin and calcitriol in a case of severe, protracted and refractory hypercalcemia due to a pancreatic neuroendocrine tumor.
Van den Eynden GG; Neyret A; Fumey G; Rizk-Rabin M; Vermeulen PB; Bouizar Z; Body JJ; Dirix LY
Bone; 2007 Apr; 40(4):1166-71. PubMed ID: 17188588
[TBL] [Abstract][Full Text] [Related]
5. Presentation of a PTHrP-secreting pancreatic neuroendocrine tumour, with hypercalcaemic crisis, pre-eclampsia, and renal failure.
Abraham P; Ralston SH; Hewison M; Fraser WD; Bevan JS
Postgrad Med J; 2002 Dec; 78(926):752-3. PubMed ID: 12509695
[TBL] [Abstract][Full Text] [Related]
6. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
Faiss S; Pape UF; Böhmig M; Dörffel Y; Mansmann U; Golder W; Riecken EO; Wiedenmann B;
J Clin Oncol; 2003 Jul; 21(14):2689-96. PubMed ID: 12860945
[TBL] [Abstract][Full Text] [Related]
7. Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers.
Giannetta E; Sesti F; Modica R; Grossrubatscher EM; Guarnotta V; Ragni A; Zanata I; Colao A; Faggiano A
Front Endocrinol (Lausanne); 2021; 12():665698. PubMed ID: 34093441
[TBL] [Abstract][Full Text] [Related]
8. Case report: lanreotide in the management of hypercalcemia of malignancy.
Anthony LB; May ME; Oates JA
Am J Med Sci; 1995 Jun; 309(6):312-4. PubMed ID: 7771500
[TBL] [Abstract][Full Text] [Related]
9. Parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumours: case series and literature review.
Srirajaskanthan R; McStay M; Toumpanakis C; Meyer T; Caplin ME
Neuroendocrinology; 2009; 89(1):48-55. PubMed ID: 18679021
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of lanreotide Autogel
Paragliola RM; Prete A; Papi G; Torino F; Corsello A; Pontecorvi A; Corsello SM
Drug Des Devel Ther; 2016; 10():3459-3470. PubMed ID: 27822010
[TBL] [Abstract][Full Text] [Related]
11. The safety of lanreotide for neuroendocrine tumor.
Godara A; Siddiqui NS; Byrne MM; Saif MW
Expert Opin Drug Saf; 2019 Jan; 18(1):1-10. PubMed ID: 30582380
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
